We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Eli ...
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...
Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...
Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) is having a terrific 2024. Shares have gained 58% so far this year, handily ...
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound were no longer ...
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...
“ (Weight loss medications) can help, for sure, but exercise and getting enough protein to make sure you aren’t losing muscle ...
It has been a long time coming: The active ingredient in the weight-loss drug Zepbound and diabetes medication Mounjaro has experienced runaway popularity, along with other GLP-1 meds like Ozempic.
Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...
Since 2021, the Obesity Action Coalition (OAC) has led a national public awareness campaign against weight bias with a goal ...